Long-term outcomes of two-stage revision with positive cultures at reimplantation

两阶段翻修术后再次植入时培养结果呈阳性的长期疗效

阅读:1

Abstract

INTRODUCTION: microbiological eradication after two-stage revision is not obtained in up to 18% of cases, yet the prognostic value of positive cultures at reimplantation remains controversial. The primary aim of the study was to evaluate outcomes of patients with positive cultures at second stage, identifying failure predictors. The secondary outcome was to compare reintervention-free survival. MATERIALS AND METHODS: this retrospective cohort study included patients treated using a two-stage protocol between 2016 and 2022. PJI was diagnosed using MSIS 2013 criteria, and treatment failure was defined according to a Delphi-based consensus. Cox regression analysis was employed to assess risk factors for failure, including Charlson Comorbidity Index (CCI); American Society of Anesthesiologists (ASA) score; age; time to reimplantation; joint; number of previous septic revisions; positive cultures number at reimplantation; a difficult to treat organism. RESULTS: 83 cases were reviewed (63 hips, 20 knees). The average interval between stages was 181 days. Over 6 years follow-up (FU), elevated BMI was the only significant predictor of failure (HR 1.19; 95% CI 1.02-1.39; p = 0.03). In contrast, positive cultures at reimplantation were not associated with an increased failure risk (p = 0.95), even in cases with multiple positive cultures (p = 0.72). CONCLUSIONS: elevated BMI at reimplantation was independently associated with subsequent failure. Clinical outcomes were not significantly associated with the presence or number of positive cultures, although smaller effects cannot be excluded given the limited sample size. These findings emphasize the importance of a patient-focused rather than culture-centered approach. LEVEL OF EVIDENCE: III.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。